0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins > B7-2 > Human-B7-2-CD86-Protein-C-Fc-Tag

Human B7-2 / CD86 Protein, Fc Tag

  • Synonym
    CD86,B7-2,B70,CD28LG2,LAB72,MGC34413
  • Source
    Human B7-2, Fc Tag (CD6-H5257) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).
    Predicted N-terminus: Leu 26
  • Molecular Characterization
    Online(Leu 26 - Pro 247) AAH40261

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 51.5 kDa. As a result of glycosylation, the protein migrates as 66-100 kDa under reducing (R) condition, and 120-140 kDa under non-reducing (NR) condition (SDS-PAGE).

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    No activity loss was observed after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human B7-2, Fc Tag (Cat. No. CD6-H5257) SDS-PAGE gel

Human B7-2, Fc Tag on SDS-PAGE under reducing (R) and no-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Human B7-2, Fc TagHuman B7-2, Fc Tag (Cat. No. CD6-H5257) ELISA bioactivity

Immobilized Human B7-2, Fc Tag (Cat. No. CD6-H5257) at 2 μg/mL (100 μL/well)can bind Human CTLA-4, Strep Tag (Cat. No. CT4-H5284) with a linear range of 1-16 ng/mL (QC tested).

Bioactivity-FACS
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that recombinant Human B7-2, Fc Tag (Cat.No. CD6-H5257) can bind to CD28 expressed on Jurkat E6.1. The concentration of B7-2 used is 2 μg/ml(Routinely tested).

FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Human B7-2, Fc Tag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing  anti-CD28 antibody. The concentration of B7-2 used is 2 μg/ml. The IC50 is 0.022 μg/ml (Routinely tested).

FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that Human B7-2, Fc Tag (Cat. No. CD6-H5257) can bind to 293T cells overexpressing human CTLA4 protein. The concentration of Human B7-2 is 3 μg/ml (Routinely tested).

  • Citations
  • Background
    Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.
  • References
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $340.00

Price(USD) : $1440.00

Promotion & Exhibitions

  • PEGS Boston 2018
  • WPC Boston 2018

B7-2 Products

  • Name:Cluster of Differentiation 86
  • Classification:Homo sapiens
  • Number of Launched Drugs:2 Details
  • Number of Drugs in Clinical Trials:8 Details
  • Lastest Research Phase:Approved
  • MORE

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop